<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232878</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-936-HV-001</org_study_id>
    <nct_id>NCT04232878</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Trial of CVL-936 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In-Human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Ascending Doses of CVL-936 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and
      pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sufficient data has been obtained to meet current objectives
  </why_stopped>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Actual">May 21, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>A sample size of 9 subjects per cohort has been chosen based on the need to minimize exposure of humans to CVL-936 and PF-06815106 and the requirement to provide adequate safety, tolerability, and PK information at each dose. Each cohort will be conducted as a crossover design with 3 periods and each cohort will have up to 6 subjects receiving CVL-936 and 3 subjects receiving placebo within each period, with a total of approximately 18 subjects if 2 cohorts complete or a total of approximately 27 subjects if 3 cohorts complete.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with reported Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Clinically significant changes in Electrocardiogram measures (PR, RR, QT and QTcF)</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Clinically meaningful changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature)</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Clinically significant changes in laboratory measures</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
    <description>Number of subjects with clinically significant changes in hematology, serum chemistry and urinalysis will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
    <description>The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent.&quot; The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Simpson-Angus Scale (SAS) Results</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
    <description>Evaluating Extrapyramidal symptoms using the SAS. The SAS consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Abnormal Involuntary Movement Scale (AIMS) Results</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
    <description>The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the subject is at rest, and the investigator also makes global judgments on the subject's dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the subject's dental status. The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of Barnes Akathisia Rating Scale (BARS) Results</measure>
    <time_frame>At the end of Period 3 (30 Days)</time_frame>
    <description>Evaluating Extrapyramidal symptoms using the BARS. The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the subject, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items are rated on a 4‑point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Substance Use Disorders (SUD)</condition>
  <arm_group>
    <arm_group_label>Active Comparator: Group 1 Period 1: 0.5mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group 1 Period 2:TBD mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group 1 Period 3:TBD mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group 2 Period 1:TBD mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group 2 Period 2:TBD mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group 2 Period 3:TBD mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group 3: TBD mg CVL-936</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension/solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Group 3: TBD mg Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo; Oral suspension/solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVL-936</intervention_name>
    <description>CVL-936</description>
    <arm_group_label>Active Comparator: Group 1 Period 1: 0.5mg CVL-936</arm_group_label>
    <arm_group_label>Active Comparator: Group 1 Period 2:TBD mg CVL-936</arm_group_label>
    <arm_group_label>Active Comparator: Group 1 Period 3:TBD mg CVL-936</arm_group_label>
    <arm_group_label>Active Comparator: Group 2 Period 1:TBD mg CVL-936</arm_group_label>
    <arm_group_label>Active Comparator: Group 2 Period 2:TBD mg CVL-936</arm_group_label>
    <arm_group_label>Active Comparator: Group 2 Period 3:TBD mg CVL-936</arm_group_label>
    <arm_group_label>Active Comparator: Group 3: TBD mg CVL-936</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Placebo matching CVL-936</description>
    <arm_group_label>Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo</arm_group_label>
    <arm_group_label>Placebo Comparator: Group 3: TBD mg Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 50
        years

        Exclusion Criteria:

          1. Subjects with a current history of significant pulmonary, gastrointestinal, renal,
             hepatic, metabolic, endocrine, hematological, immunological, psychiatric, or
             neurological disease that, in the opinion of the investigator or medical monitor,
             could compromise either subject safety or the results of the trial.

          2. Subjects with epilepsy or a history of seizures

          3. Systolic supine blood pressure ≥130 mmHg and/or supine diastolic blood pressure ≥80
             mmHg at Screening or Day -1, or orthostatic hypotension at Screening or Day -1.

          4. Subjects with a history of hypersensitivity to any dopamine-blocker medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Leoni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cerevel Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

